SCHEMBL12698265

SCHEMBL12698265

CCOc1ccccc1[C@@H]1CC(=O)Nc2cc3c(cc21)OCO3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 1.00
LMNA P02545 9/20 1.00
TSHR P16473 9/20 0.88
NPSR1 Q6W5P4 4/20 0.88
TP53 P04637 6/20 0.84
ALOX15 P16050 2/20 0.84
RAB9A P51151 2/20 0.84
MAPK1 P28482 3/20 0.74
MEN1 O00255 1/20 0.73
KMT2A Q03164 1/20 0.73
ALDH1A1 P00352 2/20 0.67
HPGD P15428 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
GAA P10253 3/20 0.62
MAPT P10636 3/20 0.62
KDM4E B2RXH2 1/20 0.62
PAX8 Q06710 1/20 0.62
POLB P06746 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29433738 1.00 SMN1; SMN2 (1.00) SMN1; SMN2LMNATSHRNPSR1TP53
SCHEMBL12469684 1.00 SMN1; SMN2 (1.00) SMN1; SMN2LMNATSHRNPSR1TP53
SCHEMBL29433753 1.00 SMN1; SMN2 (1.00) SMN1; SMN2LMNATSHRNPSR1TP53
SCHEMBL17226016 1.00 SMN1; SMN2 (1.00) SMN1; SMN2LMNATSHRNPSR1TP53
SCHEMBL21643939 0.93 TSHR (1.00) SMN1; SMN2LMNATSHRNPSR1TP53
SCHEMBL14842661 0.91 LMNA (1.00) SMN1; SMN2LMNATSHRNPSR1TP53
SCHEMBL18511516 0.90 LMNA (0.90) SMN1; SMN2LMNATSHRNPSR1TP53
SCHEMBL12469836 0.88 SMN1; SMN2 (1.00) SMN1; SMN2LMNATSHRNPSR1TP53
SCHEMBL29433766 0.88 SMN1; SMN2 (0.79) SMN1; SMN2LMNATSHRNPSR1TP53
SCHEMBL18522859 0.88 SMN1; SMN2 (0.79) SMN1; SMN2LMNATSHRNPSR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2019-08-27 US disclosed
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2018-02-22 US disclosed
US-9815845-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-11-14 US disclosed
US-9802948-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERISTY (US) 2017-10-31 US disclosed
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-04-20 US disclosed
US-9597325-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-03-21 US disclosed
US-20170044175-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-02-16 US disclosed
US-9399644-B2 [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer TRUSTEES OF BOSTON UNIVERSITY (US) 2016-07-26 US disclosed
US-20150344491-A1 [1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER TRUSTEES OF BOSTON UNIVERSITY (US) 2015-12-03 US disclosed
US-9175001-B2 [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer TRUSTEES OF BOSTON UNIVERSITY (US) 2015-11-03 US disclosed
WO-2012050985-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885LMNA 861/4885TSHR 3901/4885
US-20150344491-A1 [1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER GTF3C5, GTF2F1, GTF3C2 SMN1; SMN2 4821/4885LMNA 738/4885TSHR 2266/4885
US-20170044175-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885LMNA 861/4885TSHR 3901/4885
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885LMNA 861/4885TSHR 3901/4885
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885LMNA 861/4885TSHR 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.